ARK Genomic Revolution ETF
ARKG
387 hedge funds and large institutions have $1.09B invested in ARK Genomic Revolution ETF in 2022 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 114 increasing their positions, 159 reducing their positions, and 110 closing their positions.
2.35% more ownership
Funds ownership: 27.06% → 29.41% (+2.4%)
16% less funds holding
Funds holding: 460 → 387 (-73)
22% less capital invested
Capital invested by funds: $1.39B → $1.09B (-$300M)
28% less repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 159
48% less call options, than puts
Call options by funds: $185M | Put options by funds: $357M
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
64% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 110
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$55.9M |
| 2 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$47.7M |
| 3 |
Morgan Stanley
New York
|
+$26.5M |
| 4 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$19.8M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$19M |
| 2 |
Jane Street
New York
|
-$13.8M |
| 3 |
JP Morgan Chase
New York
|
-$10.5M |
| 4 |
CPA
Capital Planning Advisors
Roseville,
California
|
-$9.37M |
| 5 |
EP
Eversept Partners
New York
|
-$9.25M |
ARKG Hedge Fund Activity: Q1 2022 in Review
387 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q1 2022, worth a combined $1.09B — down 22% from $1.39B a quarter earlier.
Sellers outnumbered buyers: 110 funds closed out of ARKG and 40 opened new positions — a net loss of 70 holders — while 159 trimmed existing stakes and 114 added.
The largest buyer was Goldman Sachs, adding an estimated $55.9M. The largest seller was UBS Group, cutting an estimated $19M.
- 387 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q1 2022, down from 460 in Q4 2021.
- Funds reported $1.09B of ARK Genomic Revolution ETF stock for Q1 2022, down 22% quarter-over-quarter.
- 40 funds opened new ARK Genomic Revolution ETF positions in Q1 2022 and 110 closed out, a net change of -70 holders.
- The largest ARK Genomic Revolution ETF buyer in Q1 2022 was Goldman Sachs, an estimated $55.9M added.
- The largest ARK Genomic Revolution ETF seller in Q1 2022 was UBS Group, an estimated $19M sold.
Based on aggregated 13F filings for Q1 2022.